Digitization in healthcare is revolutionizing the way we prevent, treat and manage health conditions. Emerging technologies not only expedite the development of new drugs, but also introduce a completely new class of therapies, such as digital therapeutics (DTx), which are software-based solutions that can treat and support a specific disease or disorder. Digital health has a growing impact on the delivery of care and provides the opportunity to tackle the next frontier in healthcare by shifting the focus from treatment to prevention. Over the past decade there have been rapid advancements in the digital health space, which is reflected by the increasing number of emerging digital health companies and the influx of capital from private and public investors, the medical industry and governments. As a life sciences company with a track record in delivering life-changing pharmaceuticals into people’s hands, We aims to change how people experience health and care through digital health collaboration and co-creation. Clinical trials: Efficacy test with the help of Digitalization. Clinical trials help to assess the efficacy and safety of drug candidates. The lengthy, high-risk and expensive process of drug discovery and development can take a total of 10 to 15 years. The reduction of this timeframe will deliver life-enhancing medications faster to patients in need. There is no doubt that there is an urgent need to improve clinical trial efficiency. There are several points in the research and development process that technology can intervene to achieve improvements. Due to strict eligibility criteria or the rarity of a disease, identifying patients eligible for clinical study enrollment can often be a limiting factor. Electronic health records (EHR) present a great opportunity to increase patient visibility and decrease recruitment time. However, only a handful of countries, such as Estonia, have successfully executed approaches to convert handwritten physician notes, annotate information and integrate various EHR systems. Various digital health solutions can also support patients and caretakers to comply with medication intake regimen Decentralizing clinical trials to patient homes with new technologies is making clinical trials more successful. So-called ‘remote trials’ can help in recruitment, communication, data capturing and patient monitoring – all within the comfort of patients’ homes. Wearable’s can record and analyze measurements, such as vitals, and automatically share them with the study group. Smart algorithms, like that of xbird, can indicate changes in behaviour and activity patterns in patients, as shown in an observational study with pulmonology patients. Continuous outcome measurement in remote trials may better assess the efficacy of a drug candidate when compared to less frequent measurements taken during hospital visits. This approach also increases patient engagement and has the potential to decrease dropout rates. Remote trials can complement traditional approaches by considering country-specific regulations for technologies, such as telemedicine, and health regulatory guidance on evidence generation for market access. An exciting new area is the emergence of digital biomarkers. The goal is to detect or even predict health threats, such as heart conditions, based on data from mobile and/or wearable devices. In collaboration with Stanford University School of Medicine, the Apple Heart Study demonstrates Apple Inc’s ability to identify atrial fibrillation, which is a possible precursor of stroke and heart. Digital health bears exciting opportunities to identify and develop helpful new medicines. Collaboration between technology companies, the pharmaceutical industry, patient and physician groups and regulatory bodies will pave the way for further innovation in the world of medicine.